4-1BB costimulation of effector T cells for adoptive immunotherapy of cancer: Involvement of Bcl gene family members

Journal of Immunotherapy

Volumn 30, Issue 4, 2007, Pages 406-416

  Kroon, Hidde M ^a   Li, Qiao ^a   Teitz Tennenbaum, Seagal ^a   Whitfield, Joel R ^a   Noone, Anne Michelle ^b   Chang, Alfred E ^a,b  

^a Division of Surgical Oncology   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

4 1BB; Activation induced cell death (AICD); Bcl; Cytokine; T cell

Indexed keywords

CD137 LIGAND; CD28 ANTIGEN; CD3 ANTIGEN; CYTOKINE; GAMMA INTERFERON; PROTEIN BCL 2; PROTEIN BCL XL;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CANCER; CANCER IMMUNOTHERAPY; CELL DEATH; CELL FUNCTION; CELL FUSION; CELL LABELING; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFER; CONGENIC STRAIN; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; IN VIVO STUDY; INCIDENCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STAINING; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, CD137; ANTIGENS, CD28; ANTIGENS, CD3; BCL-X PROTEIN; CELL PROLIFERATION; FEMALE; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 34247639947     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31802eecc6     Document Type: Article

References (41)

1. Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst. 1999;85:622-632.
2. Chang AE, Yoshizawa H, Sakai K, et al. Clinical observations on adoptive immunotherapy with vaccine-primed T lymphocytes secondarily sensitized to tumor in vitro. Cancer Res. 1993;53:1043-1050.
3. Plautz GE, Miller DW, Barnett GH, et al. T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res. 2000;6:2209-2218.
4. Lind SD, Tuttle TM, Bethke KP, et al. Expansion and tumor specific cytokine secretion of bryostatin-activated T-cells from cryopreserved axillary lymph nodes of breast cancer patients. Surg Oncol. 1993;2:273-282.
5. Chang AE, Aruga A, Cameron MJ, et al. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol. 1997;15:796-807.
6. Li Q, Grover A, Donald EJ, et al. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells. J Immunology. 2005;175:1424-1432.
7. Chang AE, Li Q, Jiang G, et al. Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell carcinoma. J Clin Oncol. 2003;21:884-890.
8. Li Q, Furman SA, Bradford CR, et al. Expanded tumor-reactive CD4+ T-cell responses in human cancers induces by secondary anti-CD3/anti-CD28 activation. Clin Cancer Res. 1999;5:461-469.
9. + cells generated from tumor-primed lymph nodes using Anti-CD3/Anti-CD28 monoclonal antibodies. J Immunother. 2002;25:304-313.
10. Ito F, Carr A, Svensson H, et al. Antitumor reactivity of anti-CD3/anti-CD28 bead-activated lymphoid cells: implications for cell therapy in a murine model. J Immunother. 2003;26:222-233.
11. Aruga A, Aruga E, Tanigawa K, et al. Type 1 versus type 2 cytokine release by Vβ T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role. J Immunol. 1997;159:664-673.
12. Li Q, Carr A, Chang AE. Synergistic effects of IL-12 and IL-18 in skewing tumor-reactive T cell responses toward a type 1 pattern. Cancer Res. 2005;65:1063-1070.
13. Li Q, Carr A, Ito F, et al. Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy. Cancer Res. 2003;63:2546-2552.
14. Marsden VS, Strasser A. Control of apoptosis in the immune system: Bcl-2, BH3-only proteins and more. Ann Rev Immunol. 2003;21:71-105.
15. Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the Bcl-2 family and cell death. Blood. 1996;88:386-401.
16. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993;74:609-619.
17. Cheng EH, Wei MC, Weiler S, et al. Bcl-2, Bcl-xL sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell. 2001;8:705-711.
18. Yamamoto K, Morishita S, Hayashi H, et al. Contribution of Bcl-2, but not Bcl-xL and Bax, to anti-apoptotic actions of hepatocyte growth factor in hypoxia-conditioned human endothelial cells. Hypertension. 2001;37:1341-1348.
19. Boise LH, Gonzalez-Garcia M, Postema CE, et al. Bcl-x, a Bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell. 1993;74:597-608.
20. VanderHeiden MG, Chandel NS, Williamson EK, et al. Bcl-xL regulates the membrane potential and volume homeostasis of mitochondria. Cell. 1997;91:627-637.
21. Kuwana T, Mackey MR, Perkins G. Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell. 2002;111:331-342.
22. Wang JL, Liu D, Zhang ZJ, et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA. 2000;97:7124-7129.
23. Chan SL, Lee MC, Tan KO, et al. Identification of chelerythrine as an inhibitor of Bcl-xL function. J Biol Chem. 2003;278:20453-20456.
24. low cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes. J Immunol. 1998;160:3444-3452.
25. Chirathaworn C, Kohlmeier JE, Tibbetts SA, et al. Stimulation through intercellular adhesion molecule-1 provides a second signal for T cell activation. J Immunol. 2002;168:5530-5537.
26. Ankersmit HJ, Deicher R, Moser B, et al. Impaired T cell proliferation, increased soluble death-inducing receptors and activation-induced T cell death in patients undergoing haemodialysis. Clin Exp Immunol. 2001;125:142-148.
27. Lin SJ, Yu JC, Cheng PJ, et al. Effect of interleukin-15 on anti-CD3/anti-CD28 induced apoptosis of umbilical cord blood CD4+ T cells. Eur J Haematol. 2003;71:425-432.
28. Erlacher M, Knoflach M, Stec IE, et al. TCR signaling inhibits glucocorticoid-induced apoptosis in murine thymocytes depending on the stage of development. Eur J Immunol. 2005;35:3287-3296.
29. Mittal A, Papa S, Franzoso G, et al. NF-kappaB-dependent regulation of the timing of activation-induced cell death of T lymphocytes. J Immunol. 2006;176:2183-2189.
30. Rasooly R, Schuster GU, Gregg JP, et al. Retinoid x receptor agonists increase bcl2a1 expression and decrease apoptosis of naive T lymphocytes. J Immunol. 2005;175:7916-7929.
31. Xie H, Huang Z, Sadim MS, et al. Stabilized beta-catenin extends thymocyte survival by up-regulating Bcl-xL. J Immunol. 2005;175:7981-7988.
32. Reed JC. Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin North Am. 1995;9:451-474.
33. Ryan JJ, Prochovnik E, Gottlieb CA, et al. C-myc and Bcl-2 modulate p53 function by altering p53 subcellular trafficking during the cell cycle. Proc Natl Acad Sci USA. 1994;91:5878-5882.
34. Chang WK, Yang KD, Chuang H, et al. Glutamine protects activated human T cells from apoptosis by up-regulating glutathione and Bcl-2 levels. Clin Immunol. 2002;104:151-160.
35. Charo J, Finkelstein SE, Grewal N, et al. Bcl-2 overexpression enhances tumor-specific T-cell survival. Cancer Res. 2005;65:2001-2008.
36. Hurtado JC, Kim YJ, Kwon BS. Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death. J Immunol. 1997;158:2600-2609.
37. Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of cDNA's for Bcl-2 and a hybrid Bcl- 2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell. 1986;47:19-28.
38. Lee H-W, Nam K-O, Seo SK, et al. 4-1BB cross-linking enhances the survival and cell cycle progression of CD4T lymphocytes. Cell Immunol. 2003;223:143-150.
39. Lee H-W, Park S-J, Choi BK, et al. 4-1BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xl and Bfl-1. J Immunol. 2002;169:4882-4888.
40. Takahashi C, Mittler RS, Vella AT. 4-1BB is a bona fide CD8T cell survival signal. J Immunol. 1999;162:5037-5040.
41. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncology. 2005;23:2346-2357.